HIGHLIGHTS
- who: HER and collaborators from the Department of Medicine, Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA have published the paper: Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer, in the Journal: (JOURNAL)
- what: The study has several limitations to be noted. The data may have been skewed by the 27 patients receiving T + L, since the patients on this trial had lower rates of pCR compared with the other included trials, consistent with published data suggesting . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.